| Description | Relatlimab(BMS-986016) is a monoclonal antibody targeting human anti-LAG-3, generated by immunization of transgenic mice with human immunoglobulin carrying recombinant LAG-3 protein.Relatlimab has a blocking effect, blocking the interaction of LAG-3/MHC II (IC50: 0.67 nM) and LAG-3/FGL1 (IC50: 0.019 nM). Relatlimab is often used with Nivoluma to treat advanced melanoma. |
| In vitro | Relatlimab（0.001-100 nM）能够识别天然的LAG-3，并与初级激活的人类及猕猴CD4+ T细胞结合，其EC50值分别为0.11 nM和29.11 nM。Relatlimab（0.001-10000 nM；3A9-hLAG-3）增强了T细胞杂交瘤3A9-hLAG-3的肽活性，并逆转了lag-3介导的T细胞杂交瘤3A9-hLAG-3的抑制效应，IC50值为1.05 nM。此外，Relatlimab（0.001-10000 nM；初级T细胞）在超抗原刺激的人类PBMC培养中增强了激活并促进了IL-2的分泌。 |
| Synonyms | BMS-986016 |
| molecular weight | N/A |
| CAS | 1673516-98-7 |
| Storage | store at low temperature | store at -20°C |
| References | 1. Thudium K, et al. Preclinical Characterization of Relatlimab, a Human LAG-3-Blocking Antibody, Alone or in Combination with Nivolumab. Cancer Immunol Res. 2022 Oct 4;10(10):1175-1189. |